Patents by Inventor Hemant H. Alur
Hemant H. Alur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230093154Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: ApplicationFiled: September 6, 2022Publication date: March 23, 2023Inventors: Hemant H. Alur, James AH Harwick
-
Patent number: 11458113Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: GrantFiled: July 7, 2019Date of Patent: October 4, 2022Assignee: Trilogic Pharma LLCInventors: Hemant H. Alur, James A H Harwick
-
Publication number: 20220040306Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.Type: ApplicationFiled: August 23, 2021Publication date: February 10, 2022Inventors: Hemant H. ALUR, James A. H. Harwick
-
Patent number: 11129896Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.Type: GrantFiled: July 18, 2016Date of Patent: September 28, 2021Assignee: Trilogic Pharma LLCInventors: Hemant H. Alur, James A. H. Harwick
-
Publication number: 20190328688Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: ApplicationFiled: July 7, 2019Publication date: October 31, 2019Inventors: Hemant H. Alur, James AH Harwick
-
Patent number: 10383833Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: GrantFiled: October 9, 2017Date of Patent: August 20, 2019Assignee: Milanapharm LLCInventors: Hemant H Alur, James A H Harwick
-
Patent number: 10039709Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.Type: GrantFiled: June 2, 2011Date of Patent: August 7, 2018Assignee: TRILOGIC PHARMA LLCInventors: Hemant H. Alur, James A. H. Harwick, Mondal Pravakar, Thomas P. Johnston
-
Publication number: 20180207275Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.Type: ApplicationFiled: July 18, 2016Publication date: July 26, 2018Inventors: Hemant H. ALUR, James A. H. Harwick
-
Publication number: 20180104200Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: ApplicationFiled: October 9, 2017Publication date: April 19, 2018Inventors: Hemant H. Alur, James AH Harwick
-
Patent number: 8691278Abstract: Provided are bioerodible compositions that can be implanted into cavities or mammalian tissue as a liquid or semi-liquid and which solidify upon exposure of the body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.Type: GrantFiled: July 12, 2013Date of Patent: April 8, 2014Assignee: Trilogic Pharma LLCInventors: Hemant H. Alur, James A. H. Harwick, Pravakar Mondal, Thomas P. Johnston
-
Publication number: 20130338088Abstract: Provided are bioerodible compositions that can be implanted into cavities or mammalian tissue as a liquid or semi-liquid and which solidify upon exposure of the body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.Type: ApplicationFiled: July 12, 2013Publication date: December 19, 2013Applicant: TriLobic Pharma LLCInventors: Hemant H. Alur, James A.H. Harwick, Pravakar Mondal, Thomas P. Johnston
-
Patent number: 8501230Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.Type: GrantFiled: December 2, 2008Date of Patent: August 6, 2013Assignee: TriLogic Pharma LLCInventors: Hemant H. Alur, James A. H. Harwick, Pravakar Mondal, Thomas P. Johnston
-
Patent number: 8461210Abstract: A pharmaceutical composition such as a swallow tablet or capsule formulation is described comprising paracetamol, calcium carbonate, at least one binding agent and at least one disintegrating agent in the form of a granulate, optionally combined with one or more pharmaceutically acceptable extragranular components.Type: GrantFiled: April 3, 2007Date of Patent: June 11, 2013Assignee: GlaxoSmithKline, LLCInventor: Hemant H. Alur
-
Publication number: 20130131166Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.Type: ApplicationFiled: June 2, 2011Publication date: May 23, 2013Applicant: TRILOGIC PHARMA LLCInventors: Hemant H. Alur, James A.H. Harwick, Mondal Pravakar, Thomas P. Johnston
-
Publication number: 20100324110Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.Type: ApplicationFiled: December 2, 2008Publication date: December 23, 2010Applicant: TriLogic Pharma LLCInventors: Hemant H. Alur, James A.H. Harwick, Pravakar Mondal, Thomas P. Johnston
-
Publication number: 20090170955Abstract: A pharmaceutical composition such as a swallow tablet or capsule formulation is described comprising paracetamol, calcium carbonate, at least one binding agent and at least one disintegrating agent in the form of a granulate, optionally combined with one or more pharmaceutically acceptable extragranular components.Type: ApplicationFiled: April 3, 2007Publication date: July 2, 2009Inventor: Hemant H. Alur
